British journal of haematology

publication venue for

CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). 2007
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study. 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. 2024
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. 2024
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. 2024
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. 2024
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. 2023
Natural history of blood pressure in sickle cell disease pregnancy. 2023
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation. 2023
ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells. 2023
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. 2023
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy. 2023
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.. 196. 2021
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.. 192. 2020
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.. 191. 2020
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.. 191. 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.. 190. 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.. 189. 2020
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.. 190. 2020
An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease.. 189. 2020
Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).. 189. 2020
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.. 188. 2019
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.. 186. 2019
Acute myeloid leukaemia niche regulates response to L-asparaginase.. 186. 2019
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.. 185. 2019
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).. 185. 2019
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.. 185. 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.. 184. 2018
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.. 184. 2018
Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).. 183. 2018
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.. 183. 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.. 182. 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.. 182. 2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.. 182. 2018
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.. 181. 2018
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.. 181. 2018
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.. 181. 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.. 180. 2018
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.. 179. 2017
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.. 179. 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.. 178. 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.. 178. 2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. 177. 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.. 177. 2017
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. 176. 2016
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.. 176. 2016
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.. 176. 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. 175. 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.. 175. 2016
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia.. 175. 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.. 174. 2016
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.. 173. 2016
Central nervous system involvement in AIDS-related lymphomas.. 173. 2016
Monoclonal gammopathy-associated pure red cell aplasia.. 173. 2016
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.. 174. 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.. 173. 2016
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.. 172. 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.. 172. 2015
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.. 171. 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.. 171. 2015
Human herpesvirus 6 infection in a bone marrow biopsy specimen after allogeneic stem cell transplantation.. 171. 2015
Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke.. 171. 2015
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.. 170. 2015
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.. 170. 2015
Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy.. 170. 2015
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.. 168. 2014
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia.. 168. 2014
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.. 168. 2014
In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.. 168. 2014
A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?. 167. 2014
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.. 166. 2014
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.. 166. 2014
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.. 166. 2014
Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia.. 166. 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.. 165. 2014
Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma.. 164. 2013
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.. 164. 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. 163. 2013
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.. 163. 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.. 163. 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.. 162. 2013
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.. 162. 2013
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.. 162. 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.. 162. 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.. 161. 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.. 161. 2013
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.. 161. 2013
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).. 160. 2012
Increased leucocyte apoptosis in transfused β-thalassaemia patients.. 160. 2012
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).. 160. 2012
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.. 158. 2012
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array.. 156. 2011
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.. 155. 2011
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.. 155. 2011
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.. 154. 2011
Integrated profiling of diffuse large B-cell lymphoma with 7q gain.. 153. 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.. 153. 2011
Renal dysfunction in patients with thalassaemia.. 153. 2011
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.. 153. 2011
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.. 151. 2010
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.. 151. 2010
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.. 150. 2010
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma.. 149. 2010
Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura.. 149. 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.. 148. 2010
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.. 148. 2009
Genome wide DNA-profiling of HIV-related B-cell lymphomas.. 148. 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.. 146. 2009
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.. 146. 2009
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.. 146. 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.. 146. 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.. 146. 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.. 145. 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.. 145. 2009
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.. 144. 2008
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. 143. 2008
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.. 143. 2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.. 143. 2008
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.. 143. 2008
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone.. 143. 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.. 143. 2008
Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.. 142. 2008
The effect of anti-CD40 ligand in immune thrombocytopenic purpura.. 141. 2008
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.. 140. 2008
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.. 139. 2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.. 139. 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.. 138. 2007
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.. 138. 2007
Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.. 138. 2007
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.. 138. 2007
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.. 137. 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.. 137. 2007
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.. 137. 2007
Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate.. 136. 2006
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.. 135. 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. 134. 2006
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.. 133. 2006
Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21).. 133. 2006
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.. 132. 2006
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.. 130. 2005
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.. 130. 2005
Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia.. 130. 2005
Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas.. 129. 2005
Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease.. 127. 2004
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.. 127. 2004
Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists.. 127. 2004
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.. 125. 2004
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.. 125. 2004
t(11;18)(q21;q21) of mucosa-associated lymphoid tissue lymphoma results from illegitimate non-homologous end joining following double strand breaks.. 125. 2004
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.. 125. 2004
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.. 124. 2004
Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.. 124. 2004
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.. 124. 2004
Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy.. 123. 2003
Beta7E-beta132K salt bridge and sickle haemoglobin stability and conformation.. 122. 2003
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.. 122. 2003
High frequency of t(11;18) in gastric mucosa-associated lymphoid tissue lymphomas in Taiwan, including one patient with high-grade transformation.. 120. 2003
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.. 119. 2002
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units.. 119. 2002
High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura.. 118. 2002
Beta(2)-microglobulin as a negative growth regulator of myeloma cells.. 118. 2002
Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults.. 118. 2002
Optimizing dendritic cell-based immunotherapy in multiple myeloma.. 117. 2002
Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia.. 117. 2002
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.. 116. 2002
beta-Spectrin S(ta) Bárbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism.. 115. 2001
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.. 112. 2001
Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.. 112. 2001
Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma.. 112. 2001
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.. 111. 2000
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma.. 109. 2000
Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia.. 108. 2000
Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc.. 107. 1999
Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells.. 100. 1998
Expression of interleukin-5 by human bone marrow microvascular endothelial cells: implications for the regulation of eosinophilopoiesis in vivo.. 99. 1997
Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy.. 99. 1997
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.. 97. 1997
Collection of peripheral blood stem cells from normal donors 60 years of age or older.. 97. 1997
Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets.. 96. 1997
Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation.. 96. 1997
Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome.. 93. 1996
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.. 92. 1996
Serum levels of GM-CSF are elevated in patients with thrombocytopenia.. 92. 1996
Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma.. 89. 1995
Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests.. 89. 1995
Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group.. 87. 1994
High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.. 83. 1993
18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance.. 72. 1989
In vitro interferon-gamma production by cultured T-cells in severe aplastic anaemia: correlation with granulomonopoietic inhibition in patients who respond to anti-thymocyte globulin.. 69. 1988
In vitro multimerization of human von Willebrand factor from its subunits.. 67. 1987
DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukaemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation.. 60. 1985
Disproportionate lymphoid cell subsets in thalassaemia major: the relative contributions of transfusion and splenectomy.. 59. 1985
Serum transcobalamin levels as an early indicator of bone marrow engraftment following transplantation.. 55. 1983
ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation.. 54. 1983
SV40 T-antigen expression in acute non-lymphocytic leukaemia.. 43. 1979
Association of IgA multiple myeloma with pre-existing disease.. 41. 1979
Myosin in cultured human endothelial cells.. 35. 1977
Platelet dysfunction in vincristine treated patients.. 32. 1976
The effect of platelet membrane antibodies on aggregation and release.. 28. 1974
Immunological studies of proteins associated with the subcellular fractions of thrombasthenic and afibrinogenaemic platelets.. 15. 1968
Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.. 194. 2021
Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients.. 190. 2020
Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children.. 189. 2020
A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathy.. 189. 2020
Kidney transplantation in AL Amyloidosis: is it time to maximize access?. 188. 2019
FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency.. 186. 2019
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.. 186. 2019
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.. 185. 2018
Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.. 185. 2018
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.. 182. 2017
The safety of chronic antithrombotic therapy in patients with factor XI deficiency.. 179. 2016
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.. 178. 2016
Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor.. 173. 2015
A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.. 168. 2014
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.. 162. 2013
Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up.. 162. 2013
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.. 158. 2012
Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis.. 155. 2011
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera.. 130. 2005
Immune thrombocytopenic purpura: investigation of the role of cytomegalovirus infection.. 126. 2004
Endothelial cell activation and apoptosis in the thrombotic microangiopathies.. 125. 2004
Maternal IVIG in neonatal alloimmune thrombocytopenia.. 98. 1997
Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. 2023
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study. 2021
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. 2018
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. 2017
Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene. 2015
Unreliable oral glucose tolerance test and haemoglobin A1C in beta thalassaemia major--a case for continuous glucose monitoring? 2013
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. 2012
Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. 2011
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. 2008
Immune thrombocytopenia: a need for assisted suicide.. 176. 2016
Haemophilia: factoring in new therapies. 2021
Checkpoint inhibitors in AML: are we there yet? 2019
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. 2015
Genetic strategies for the treatment of sickle cell anaemia. 2011
Refractory immune thrombocytopenic purpura: current strategies for investigation and management. 2008
Inhibitor development in haemophilia B: an orphan disease in need of attention. 2007
Advances in the management of alloimmune thrombocytopenia. 2007
The pathogenesis of immune thrombocytopaenic purpura. 2006
Molecular mechanisms of fibrinolysis. 2005
Bone marrow histopathology in peripheral T-cell lymphomas. 2004
Angioimmunoblastic T-cell lymphoma. 2003
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. 2000
Genetic treatment of the haemoglobinopathies: recombinations and new combinations. 1997
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis. 2024
The power and perils of large language models in haematology. 2024
Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia. 2023
Thalassaemia-A global view. 2023
Therapeutic use of regulatory T cells for graft-versus-host disease. 2019
Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. 2018
Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. 2016
Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. 2015
Sickle cell disease: time for a closer look at treatment options? 2013
Coagulation and metastasis: what does the experimental literature tell us? 2013

VIVO Weill Cornell Medical College

British journal of haematology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)